18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Assessment of CRPC Response Through Comprehensive Characterization Using Novel Biomarkers (PET CRPC)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02121600
• Other study ID #: PET CRPC
• Status: Terminated
• Phase: N/A
• Start date: September 2014
• Est. completion date: March 2018

Study information

• Verified date: May 2019
• Source: Lawson Health Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the ability of 18F-FCH PET/MRI scan to detect pre-treatment tumor burden and assess response to treatment in men with castration resistant prostate cancer (CRPC).

It is hypothesized that these novel biomarkers will better identify evaluable lesions prior to therapy and identify response to treatment (or lack thereof) earlier in the treatment period, providing a better guide for treating men with CRPC.

Description:

Castrate resistant prostate cancer (CRPC) occurs when prostate cancer no longer responds to androgen deprivation therapy. Eventually all men diagnosed with CRPC will succumb to their disease. While many new therapies have been introduced, there are limitations in assessing treatment response and physicians are faced with a challenge when creating a management strategy for men with CRPC.

Most men present with bone metastases, and accurate quantification of disease burden can be difficult due to the nature of conventional scans such as CT and bone scan. In addition, the standard blood PSA measurement does not always reflect a clinical response, or may lag to show this response. There is a clear need for better imaging and blood biomarkers to measure disease in men with CRPC.

This study will explore the benefit of a 18F-FCH Hybrid PET/MRI scan, Cancer Microparticle (CMP) and Circulating Tumor Cell (CTC) measurements compared to standard imaging and PSA levels.

In this study, patients will receive a 18F-FCH PET/MRI or 18F-FCH PET/CT scan + whole body MRI at baseline and after 12 weeks of treatment. Serial CMP and CTC blood samples will be taken at 5 study timepoints.

66 patients will be enrolled at 3 cancer centres in Ontario. Patients will be divided into 2 cohorts based on the type of treatment they will receive: Docetaxel or Abiraterone.

It is hypothesized that these novel biomarkers will better identify evaluable lesions prior to therapy and identify response to treatment (or lack thereof) earlier in the treatment period thus providing a better guide for treating men with CRPC.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: March 2018
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age or older

• Patient with CRPC and experiencing disease progression as defined by PCWG2

• ECOG 0-2

• Must continue gonadal castrative therapy

• Has completed antiandrogen withdrawal = 6 weeks prior to registration

• Metastatic disease documented by imaging

• Patient is planned for treatment with docetaxel or abiraterone

• If treated with bisphosphonates or denosumab, has been on these for = 6 weeks.

• Must provide written informed consent

Exclusion Criteria:

• Prior history of invasive malignant disease unless disease free for at least 5 years, with the exception of non-melanoma skin cancer

• Planned for any concurrent anticancer treatment oher than docetaxel or abiraterone

• Prior radiotherapy or surgery within 4 weeks of start of docetaxel or abiraterone

• Inability to comply with the imaging requirements (eg. inability to lie supine for one hour)

• Allergy to MRI contrast agent or PET tracer to be used as part of the imaging

• Sickle cell disease or other hemoglobinopathies

• Insufficient renal function (eGFR = 30 mL/min)

• Known residual bladder volume > 150 cc

• Hip prosthesis or intrabdominal vascular grafting

• Contraindication to CT contrast

• Contraindication to MRI as per institutional policy

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Other:
• [F-18]-FCH
Before the PET/MRI or PET/CT scan, patients will receive an [F-18]-Fluorocholine injection in the arm.

Radiation:
• PET scan
A whole body PET scan will be performed, combined with either whole body MRI or CT scan. This will be performed at baseline and after 12 weeks of treatment
• MRI scan
Whole body MRI scan will be performed. This may be combined with PET scan or may be performed separately. MRI scan will be done at baseline and after 12 weeks of treatment

Locations

Country	Name	City	State
Canada	Juravinski Cancer Centre	Hamilton	Ontario
Canada	London Regional Cancer Program	London	Ontario
Canada	Princess Margaret Cancer Centre	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Lawson Health Research Institute	OICR

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Percentage of change in clinical management based on results of 18F-FCH PET/MRI and CTC results		3 years
Other	Concordance of identified lesions on hybrid PET/CT + fused MRI vs hybrid PET/MRI		3 years
Other	Concordance between CTC values on a new microfluidics-based CTC assay and the FDA/Health Canada approved CellSearch CTC assay (clinical gold standard)		3 years
Primary	Number of lesions detected with 18F-FCH PET/MRI compared to conventional imaging		3 years
Secondary	Number of concordant lesions identified on identified on 18F-FCH PET, conventional imaging and MRI		3 years
Secondary	Concordance between number Circulating Tumor Cells (CTCs) and Cancer Microparticles (CMPs) and number of lesions detected by PET/MRI and conventional imaging	At both baseline and after 12 weeks of treatment	3 years
Secondary	Change in number and size of lesions after 12 weeks of treatment	As detected by 18F-FCH PET/MRI and change in CTC and CMP values	3 years
Secondary	Progression Free Survival	Changes in lesion parameters on PET and MRI and changes in serial CTC and CMP levels will be assessed to see if they are predictive of progression free survival	6 years
Secondary	Overall Survival	Changes in lesion parameters on PET and MRI and changes in serial CTC and CMP levels will be assessed to see if they are predictive of overall survival	6 years